Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HNRC Update December 11, 2023
Emerging Independent Oil & Gas Powerhouse in Permian Basin
HOUSTON, Dec. 11, 2023 /PRNewswire/ -- Houston Natural Resources Corp (OTC: HNRC) ("the Company") has announced that its portfolio company HNR Acquisition Corp ("HNRA") has completed a business combination on November 15, 2023 by purchasing all the equity interests in Pogo Resources, LLC and its subsidiary, LH Operating, LLC (collectively "LHO").
HNRA is now an independent oil and natural gas company focused on the acquisition, development, exploration and production of oil and gas properties in the Permian Basin. The Company's assets include its interest in the Grayburg-Jackson oil field in the prolific Permian Basin in New Mexico.
LHO was a privately owned company that operated the Grayburg-Jackson field (the "field") from early 2020 after acquiring the property in late 2019. The 2020 baseline production level was approximately 500 barrels of oil equivalent (BOE) per day. LHO's production has increased from the baseline 500 BOE to an average of 1,388 BOE per day for the nine months ended September 30, 2023. All field production of the Company is being sold under long-term contracts to various customers in the USA.
LHO had $20.3 million in revenues generating positive cash flow and $3.9 million of net income for the nine months ended September 30, 2023. As of September 30, 2023, total assets of LHO were $70.4 million. With the acquisition now completed, HNRA will report its first consolidated financials for the fiscal year ended December 31, 2023. The results from the acquisition will only be included for six (6) weeks of the fourth quarter in the fiscal year ended December 31, 2023.
Following the acquisition all of the experienced field personnel of LHO who achieved these results have remained with the Company
You mean like the SCAM that YOU ARE!
By the way, does your vocabulary extend beyond the word "scam?" Seems like it's the ONLY word you know! LOL!
Very clearly you're uneducated and probably never finished the 3rd grade and also can't qualify to work a REAL JOB!
How terribly you're being used & abused by your handlers who laugh at you DAILY but you don't have a choice if you want to buy a Happy Meal at McDonald's daily and dumpster dive afterwards! Do they let you use their restroom?? Probably not!
Have you considered collecting bottles and cans on the street to supplement your "income?" It might help!
LOL!
Here comes CNRC to begin trading soon with multiple revenue sources and a NAV of $3.35/Share from the GetGo! This is the closest thing you'll get to an IPO! Easy $2/$3- 2024. At $1 that would be a 3,900% Gain and at $2 a 7,900% Gain relative to today's share price $0.025. Jump aboard this Bullet Train now before it leaves the station with you standing on the tracks kicking yourself saying "wish I could of should of." Then there's Uplisting to NASDAQ or OTCQB/OTCQX first Quarter 2024 based on recent Emerging Growth Conference discussions by company leadership! Won't be long now!
IGNORE THE PAID BASHERS HERE that make just enough money per day to buy a McDonalds Happy Meal!
You mean similar to YOURSELF!
Not in his case
$HNRC $CNRC EPS has jumped from Q1-23 to Q3-23 by 400%
Re-cap (Post Merger/Acquisition)
Earnings Per Share
Q1-23: $0.03
Q3-23: $0.15
400% increase
Calculated percentage change from Starting Value of 0.03 to Final Value of 0.15
(Final - Start)/Start × 100
= (0.15 - 0.03)/0.03 × 100
= 0.120/0.03 × 100
= 4 × 100
= 400% increase
Q-3 O/S = 135,129,768 (current)
Q-2 O/S = 117,796,433
Increase = 17,333,335
Float Unchanged Q-2 to Q-3
44,675,063
This Merger Acquisition conglomerate holds extraordinary promise of explosive earnings with substantial increases in share price as it's mining and oil producing agenda proceeds!
The low Float is an added bonus and hopefully dilution will be kept at a minimum
Well said!! No worries!! We hold the GOLD!
ALL else is vanity from the fraudsters on this message board who have multiple aliases with their !ame transparent goofy con scraping nickles together justr to eat at McDonald's at the end of their shift then under the parking lot dumpster for the night! LOL!
Cheers!!
UP FROM HERE!
He has a very limited vocabulary too!
i.e. "scam", "turd", "fraud", etc all of which describes himself to the letter!
This places him somewhere between a 1st grader and a babbling toddler!
This is how his handlers abuse him terribly for peanuts!
Thus his "hand-to-mouth"...."pillar-to-post"...wandering HOBO lifestyle!
How Hilarious!!!
Notice the Resident HOBO's Limited Vocabulary...
....that centers on self projection, i.e. scam
...his I.Q. is somewhere between a Mule and a Billy Goat although the Mule is slightly more intelligent
...no doubt he's been in and out of several Mental Hospitals for reason no State appointed Psychiatrist is willing waste their time on him, plus he's broke, so this message board is his only form of "therapy"...and survival where he scrapes nickles & dimes from his abusive handlers for his bashing just enough to afford a McDonald's Happy Meal at the end of his shift while they laugh at him daily!
...also notice his Multiple Personality Disorder where he talks to himself using several I.D.s which is symptomatic of his severe limitations where he's living a "hand-to-mouth"..."pillar to post" existence!
.... essentially he's no different than a circus clown Juggler that's less than entertaining! He has no self identity which this message board helps him cope with!
Ignore the mindless wandering HOBO BUM...
....message board resident who has multiple aliases he uses to talk to himself!
...he's the equivalent of a juggling act circus clown who doesn't have two nickles to rub together! LOL!
...can't even get a job at McDonald's as a dishwasher! LOL!
NASDAQ PR 8/9/23: HNRC FILES NAME CHANGE TO CUNNINGHAM NATURAL RESOURCES CORP
https://www.nasdaq.com/press-release/hnrc-files-name-change-to-cunningham-natural-resources-corp-2023-08-09
Houston Natural Resources Corp (OTC: HNRC) ("HNRC or the Company") announced today it has filed with FINRA for a name change to Cunningham Natural Resources Corp ("CNRC") having completed the acquisition for a 100% interest in Cunningham Energy, LLC. This merger acquisition has increased HNRC's net asset value (NAV) to $3.35 Per Share post consolidation as "CNRC."
The merger acquisition planning included Cunningham Energy completing its prior two years of audited financial statements for listing on NASDAQ or NYSE this year 2023 under the new company name ("CNRC") with an underwriting commitment of $10 Million Dollars.
CNRC's focused is centered on traditional oil & gas reserves, and energy transition materials including mining in copper, lithium, gold and other rare earth & precious metals. Overall the company's focus is global with sustainability as a core directive.
Cheers!
My instincts told me that the CEO of this company was a Scam Artist but by the way he talked. I ignored it at first and bought into the company stock over a year ago, held it for a few months, then realized by his 2nd conference call that he was in fact a scam artist, all scripted in the way he talked. Glad I bailed out before he pulled the rug from under everyone!
I highly recommend to take a look at Houston Natural Resources (HNRC) that just merged with a mid-range Oil & Gas Exploration Company that recently expaned into mining copper, lithium, gold, rare earth metals, etc, AND is about to change their official company name to Cunningham Natural Resources Corp (CNRC) and Uplist to NASDAQ by the end of this year 2023, and they believe they will be trading above $3/share. You can currently buy into HNRC pre-merger for at or near 0.10 at the time of this post. Best wishes to all!
https://finance.yahoo.com/news/hnrc-files-name-change-cunningham-142500240.html
https://hnrcholdings.gcs-web.com/
Yes, I agree, you are a scam I've been dealing with
HNRC buys remaining stake in Cunningham Energy
The deal will see HNRC rebranded to Cunningham Natural Resources Corp; a 100% Acquisition
https://www.offshore-technology.com/news/hnrc-buys-cunningham-energy/#catfish
https://www.cunninghamenergy.com/
Houston Natural Resources Corp (HNRC) has announced the acquisition of Cunningham Energy, an independent oil and gas producer.
The financial value of the cash and securities deal increases HNRC’s net asset value to $3.35 per share
In October 2022 HNRC acquired a 9.9% stake in Cunningham Energy in a cash and securities deal valued at $19.62m. Now, HNRC has acquired the remaining 90.1% stake in Cunningham Energy.
Set up in 2008, the acquired company operates and holds oil and gas interests on more than 30,000 net acres of leasehold in the Appalachian Basin.
Through a farm-out agreement, Cunningham Energy of Canada controls Marzcorp’s 75% net revenue interest holding in more than 965,000 acres in the Matapedia Valley, Gaspesie, Quebec, Canada.
UP from here!
Cheers!
You mean like YOURSELF!
Grabbed ANOTHER 10,000 shares today @ 0.09
I just luv these discount prices in light of the Net Asset Value (NAV) post Cunningham Energy Acquisition is $3.35/share and that's before Up-Listing to a Major Exchange!
Sailing fast toward 200,000k at warp speed!
Goal: Quarter Million Shares!
Great set up for a Six Figure Pay Day for anyone holding enough shares!
Not going to miss the "no brainer" run on this one!
Cheers!
What's Important is The Float Not The O/S
HNRC's public Float is only 33.7M according to the most current Quarterly Report which are the number of shares available for trading.
This is a very small Float therefore it's much easier for the share price to increase the more the stock is bought.
It's this low Float that makes a big run much easier!
The only question that remains is when HNRC changes names to Cunningham Energy, will the Share Structure remain the same "pre-Uplisting" to NASDAQ or NYSE which automatically means the share price will need to be at least $4/Share to qualify for the Up-Listing.
So it would be in the company's best interest to retire several Million Shares from the O/S to make it easier to reach a $4 Share price to pre-qualify for listing on a Major Exchange.
Agree 100%
However Uplisting to a Major Exchange requires a share price BID of at least $4. Apparently they plan on meeting that requirement in light of mention that they plan on uplisting by the end of this year 2023. There are many ways they can go about doing that including share structuring and/or share buy back.
Here's something just out today!
https://cunninghamnaturalresources.com/
It appears Cunningham is reaching out to HNRC investors to take questions anyone may have.This is an extraordinary positive development!
Nothing like being in the right place at the exact right time!
Best wishes
100% CORRECT!!!
It's absolutely HILARIOUS watching these desperate paid basher Con Artistis at work here with their lame, dishonest, and misleading arm chair posts...and to make matters more amusing, they're on this board 12+ hours daily. Oddly, this implies they're "welcome here" which has profound implications. Things are not what they seem to be, I'll just leave it at that.
A complete "Fraud" did you say??
YOU MEAN LIKE YOURSELF! LOL!
How terribly desperate you are!
By the way how are things going at McDonald"s!
How terribly weak you are with your lame multiple "peek-a-boo" Aliases!
Block Buster Announcement 7-12-23 (Name Change, Financial Audit, UpListing To NYSE or NASDAQ)
https://www.digitaljournal.com/pr/news/getnews/houston-natural-resources-otc-hnrc-powerful-details-emerge-following-major-energy-news-announcement
Houston Natural Resources (OTC: HNRC) Powerful Details Emerge Following Major Acquisitiion Completion - PRESS RELEASE - July 12, 2023
Houston Natural Resources Corp soared 11.27% on 3.5 times average 30-day volume after the company announced it completed the 100% stake acquisition in Cunningham Energy LLC. The transaction boosted the net asset value or NAV to $3.35 a share.
Following the acquisition Houston Natural Resources Corp is planning to change its name to Cunningham Natural Resources Corp. The entity would be focused on the oil and gas businesses as well as energy transition materials, which would include mining opportunities in lithium, gold, copper, and other precious and rare earth materials.
While the focus of the investments would be at a global level, the company plans list on NYSE or NASDAQ in 2023 following the completion of their current financial audit which would also be accompanied by an underwriting commitment of $10 million.
The evaluation of the oil and gas assets of Cunningham Energy was conducted by an independent engineering firm. The independently appraised value of the company's leasehold position of Cunningham Energy as of December 31, 2022, stood at $352 million. The value had been reached on the assumption that the current drilling program consisting of 68 holes would be completed.
Cunningham Energy is an independent oil and gas producer, which conducts its operations in the Appalachian Basin. It boasts of leasehold to the tune of 30,000 net acres. The company, which had been established in 2008, emerged as a major pioneer in the field of horizontal drilling in West Virginia in 2014.
In the upcoming Phase 1 development program in West Virginia, the company would need to get permits and then drill and complete 20 horizontal oil wells to take care of its lease and lease drilling obligations.
The company also has a business unit named Cunningham Energy of Canada which targets 950,000 acres of leasehold in Matapedia Valley in Quebec, Canada. It holds that interest on a 75% net revenues interest basis from Marzcorp Inc by way of an executed farmout agreement. Through this collaboration, more than $14 million had been invested into the project. Cunningham Energy is also expected to get into several joint ventures, on a deal-by-deal basis, with Viper Capital Partners.
Previously, the company had picked up a 9.9% stake in Cunningham. Yesterday, the company completed an additional 90.1% acquisition, taking the Company's total investment in Cunningham Energy LLC to a 100% interest.
The transaction had been completed through the issuance of preferred and common stock. The acquisition price also included an escrow of preferred shares in lieu of certain liabilities of Cunningham. Ryan Cunningham would continue to manage Cunningham Energy following the acquisition.
UP FROM HERE POST FINANCIAL AUDIT & UPLISTING!!! NYSE or NASDQ straight ahead!
Cheers!!!
HNRC Volume On The Rise!
Friday's Volume (6/23/23) was 492,330 Vs 10 Day Average Volume of 261,201
That's nearly DOUBLE the Average Volume!
Significant News, in particular Audited Financials, should easily send the share price North of $1.00
i.e. $1.25 to $1.60
Then there's Q-2 Earnings due to drop end of August, which IF it's on the rise should push the share price higher!
All of this is speculative but plausible
Best wishes to all
So then why don't YOU Audit them!
Please provide a detailed description of what you're suggesting...
i.e. are these numbers completely false, way off, and/or deliberately misleading, and if so provide PROOF
$$$ LOAD & HOLD $$$
It's very clear this company is moving in the right direction based on the Q1-March 23 Report
Q1-23 vs Q1-22 Year over Year comparison
Total Revenue
Q1-23: $4,178,580
Q1-22: $3,562,169
17% increase
Total Earnings
Q1-23: $2,660,713
Q1-22: $2,011,988
32% increase
Total Assets
Q1-23: $92,839,255
Q1-22: $73,973,967
25% increase
Earnings Per Share
Q1-23: $0.03
Q1-22: $0.02
50% increase
Net Asset Value (NAV)
Q1-23 $1.16/share
Q1-23: Public Float
33.7 Million
(an ultra low number of shares available to retail investors)
IMO, it would be a good idea to LOAD & HOLD!
CEO recently said he anticipates Uplisting to NASDAQ in Q2 at the end of this podcast
https://thestreetreports.com/hnrc-ceo-frank-kristan-talks-rhino-acquisition-earnings-reports-and-2023-energy-outlook-on-the-street-podcast-listen-now/
Best wishes to all!
Greetings Janetcanada from OTC ShotCaller
Just checking in to see how everyone is doing!
Hope you are well!
You're a great inspiration to many, a true humanitarian. Continue in the Faith towing the line for those in great need for this Company's vast benefits to help them escape a life self of addiction.
I still morn my dear friend losing her life over substance abuse. I spent time with her in her final days, suggested many times she get into rehab, but she resisted. Nevertheless I admired her faith and trust in God. She died in the Faith. The irony that I'm a Nephrologist (kidney specialist) and I warned her many times what could happen to her due to risk of Renal Failure, but she resisted, lost both her kidneys from cocaine abuse and died with extraordinary suffering attempting to survive 2 years with no kidneys that had to be surgically removed due to necrosis caused by the cocaine..you know the story.
I felt I could of done more like facilitating getting her into rehab, but she resisted born out a false self image. What she needed was a Resident Rehab Facility like GRST but none were in existence at that time back in the 80s.
God knows we need Ethema Health
God bless...stay in touch
I will soon re-activate Private Mail and let you know.
I'm thinking about picking up an addition 50 Million Shares in this company at the current pps 0.0004
How many shares are you now holding?
Be well and prosper...
OTC ShotCaller
CLOSED UP AGAIN ON LOW VOLUME!
$0.263+0.009 (+3.54%)
Definitely under accumulation!
Steady as she goes!
Might be 0.50 by end of week!
Cheers!
Just pulled out all stoppers bought another 20,000 shares to ADD to my stack of 10,000
Now holding 30,000 shares!
Will continue to ADD 10,000 shares per day at any pps below .50
Remember Low Float, Low O/S, High Market Capacity!
Just ADDED another 15 Million Shares! I now own 25 Million!
Some of you here seem to be forgetting that Dr. Koos intends to UPLIST! This would be his only reason for a R/S
The man has made undeniable progress with this company and he's only getting started.
Presently RGBP is nearing Debt Free Status. FACT!
Don't listen to any of the naysayers here.
Have Faith...we Hold the Gold!
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
https://autos.yahoo.com/news/regen-biopharma-scheduled-presentation-american-133000762.html
How about that! The World Renouned American Society of Hematology invited RGBP in 2014 to present it's Scientific Data at a National Medical/Scientific Conference In San Francisco relative to it's directives in cancer treatment & prevention.
SAN DIEGO, CA--(Marketwired - Dec 1, 2014) - Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Results presented will include demonstration that bone marrow cells genetically engineered to express the NR2F6 gene cause healthy cells to turn leukemic when implanted into mice. The process by which the NR2F6 gene causes healthy cells to become leukemic is associated with blocking the ability of the bone marrow cells to make red blood cells. This instead causes production of immature cells termed "proerythroblasts." Furthermore, the study demonstrates that, at a molecular level, the protein made by the NR2F6 gene needs to bind DNA in order for healthy cells to turn leukemic.
"While chemotherapy and radiation therapy non-selectively kill all replicating cells, both cancer and healthy cells, thus causing severe toxicity, targeted therapies such as kinase inhibitors (e.g.: Gleevec by Novartis $4.7 billion in 2012)1 and proteasome inhibitors (e.g.: Velcade by J&J and Takeda $2.3 billion in sales in 2012)2 specifically inhibit molecular processes of cancer cells but not other multiplying cells in the body. Dr. Christine Ichim found that the NR2F6 gene is essential for the process of cancer formation, thus potentially offering a new target for development of targeted therapies," said Dr. Thomas Ichim, Regen BioPharma's Chief Scientific Officer.
"It is important to note that when inhibition of this gene with gene silencing was performed, the leukemic cells reverted back to a state resembling non-malignant cells. Thus we believe that developing therapies that block NR2F6 could lead to a whole new class of targeted therapeutics," according to Christine Ichim, PhD.
Currently Regen BioPharma is developing small molecule inhibitors of NR2F6, as well as shRNA gene-silencing of this gene. Gene-silencing has previously been utilized by Regen BioPharma in development of its dCellVax breast cancer vaccine IND application, as well as in peer-reviewed publications that Regen has co-authored3, 4.
Intellectual property covering the use of NR2F6, as well as means of targeting it, was filed by the University of Toronto with Dr. Christine Ichim, and hematologist Dr. Richard Wells as inventors. All patent and intellectual property rights to this patent application were acquired by Regen BioPharma.
"I am enthusiastic at the rapid pace, and translationally-focused approach that Regen BioPharma is taking to turn these findings into clinically-relevant approaches to helping cancer patients," stated David Koos, Chairman & CEO. "One of the fascinating results of the experiments that will be presented is that gene-silencing of NR2F6 results not in death of the leukemic cells but a type of 'repair' in that normal blood production ensues. This approach to curing cancer by "healing" the malignancy, to my knowledge, is highly innovative and I am pleased with the strong interest in this work that we have been receiving."
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer.
Cheers!
100% CORRECT!
Either that OR a Buy Out!
One or the other is about to happen any day!
Thank you for your valuable feedback!
Best wishes
Thank your for that Revelation!
Much appreciated however I was under the impression that Eli Lilly had developed an NR2F6 Checkpoint inhibitor that's not identical to ours.
Best wishes
Thank you!
Your response to Q1/Q2 answered my question.
I was aware however of Gilead Sciences acquiring Kite for $11.9 B in 2017 if I remember the year correctly.
Thank you again for your reply and valuable input.
My only other question is do you perceive that Kite's mRNA Vaccine IP is based on the same NR2F6 Checkpoint inhibitor that RGBP's is based on, or is it a variation of it like Eli Lilly's. My understanding is that Eli Lilly & RGBP share common IP claim to NR2F6 but the molecule the !P is based on is not 100% identical. Is this the case with Kite's mRNA Cancer Vaccine IP? I have not been able to locate this specific information.
Your take on this would be much appreciated.
Best regards
Clarification Request
RE: Your comment
"I spoke with Harry Lander shortly after the Kite deal was announced and he said Regen had the identical science but about a year behind and needed 25M to get to that point. Regen has since shelved that science in favour of the two mRNA IND's they have submitted which indicates how valuable they believe they are." i.e. the CAR-T cell therapy?
Q1. Are you saying that RGBP some time ago was working on developing CAR-T cell therapy but needed $25M they didn't have to advance that biotechnology, so they shelved that science in favor of two mRNA Cancer Vaccine INDs? If so, what year was it this happened?
Q2. The "Kite Deal that was announce?" What are you referring to? What deal was that, when, and with whom?
Thank you in advance for your response
Sincere regards
Well said!
You're 100% CORRECT!!!
.....and that's EXACTLY what's about to happen!
Great opportunity to pick up yet another Million Shares!
Closing in FAST on 10 Million!
Thanks!
Great Post!
I concur 100%
The recent Historical Sloan Kettering New York clinical trial utilizing a Check Point Inhibitor derived Monoclonal Antibody "Dostarlimab", via I.V. infusion that resulted in 100% cure of deadly colon cancer in all 14 patients, is a hands down testimony to the power of Check Point Inhibitor Immunotherapy that's now a matter of scientific-clinical record. The first ever in the cure-full remission of a well known deadly cancer that ranks #2 in the world as the most deadly cancer known. Lung cancer is #1.
What this represents is a "Paradigm Shift" in the Clinical Practice of medicine where historically deadly or incurable diseases in particular cancers, can now be cured via Check Point Inhibitor Immunotherapy.
I've been saying this repeatedly for a very long time that the day is going to soon come when incurable diseases, in particular deadly cancers, will be easily cured or controlled via advancing biotechnology, and that FINALLY JUST HAPPENED like I said it would and this is owed to my professional background as a physician-Big Pharma Industry Principal Investigator who has designed and conducted scores of BP clinical trials and is steep in Biotechnology Research that extends to molecular biology.
We are going to see more of this as the knowledge of Immunotherapy progresses relative to dozens of types of cancers. But curing deadly colon cancer is a great start!
Regen Biopharma had collaboration with Eli Lilly back in 2016 over their Check Point Inhibitor NR2F6 which they share common IP claim on, and it was Lilly that approached Regen to enter into a collaboration on a drug discovery program whereby Lilly provided Regen 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program in an attempt to identify "Activators" & "Inhibitors" of this protein.
Fast forward to today, the Check Point Inhibitor that Lilly & Regen have joint IP Claim on but relative to different pathways, may be the "pieces of the puzzle" that will reveal a capacity to cure a broader range of cancers than colon cancer revealed in the Sloan Kettering clinical trial. Therefore, it would behoove Lilly to Buy Out Regen if for anything, just to own Regen's IP which could prove of epic value to them in the Trillion Dollar Range upon reaching Market. Either way, Regen will go forward with or without Lilly and I would be surprise if Regen is soon acquired by a Large Cap BP like Gilead Sciences, who in 2017 acquired Kite Pharma for nearly $12 Billion that included their mRNA Cancer Vaccine IP. If Eli Lilly isn't careful they're going to miss a serious opportunity to own Regen's Check Point Inhibitor IP which recently transitioned into a Master Patent when Dr. Koos filed the updated patent for:
"mRNA Cancer Vaccine Checkpoint Inhibitor Immunotherapy" which is a "clinical use" application. This type of patent will require any pharmaceutical company that develops an mRNA Cancer Vaccine to pay Regen Royalties if they develop a Checkpoint Inhibitor as an Immunotherapy, Merk did the same thing in 1989 when they were granted an exclusive clinical use "Master Patent" for HMG CoA Reductase Inhibitor which is the basis for ALL Statins on the Market today of which there are at least 5. Each Big Pharma that manufactures an HMG Co-A Reductase Inhibitor (i.e. a Statin) under their exclusive formulary are still required to pay Merk Royalities to this very day. That patent earned Merk over $500B in revenues owed to their Master Patent. The same will apply to Regen's Master Patent IP clinical application of an mRNA Cancer Vaccine Checkpoint Inhibitor Immunotherapy described above. Dr. Koos revealed his foresight and genius in doing this!
So yes, a Buy Out for $5+ Dollars is not at all unreasonable. In fact it's a frickin bargin when you consider that this single Patent has a global Market Capacity in the Trillion Dollar Range that can be straight up owned by a Big Pharm who moves quickly to acquire Regen Biopharma just like Gilead Science did in 2017 when they acquired Kite for $11.9 Billion to be exact!
Thank you for your valuable input!
Best wishes
....be well and prosper
Best wishes
...be well and prosper
That's a very big probability seeing that Lilly lost $900M in the partnership with Curevac to develop an mRNA Cancer Vaccine that went bust due to faulty research data on Curevac's behalf. They ended their partnership abruptly in June 2020 that started in 2017, so quite naturally Lilly would naturally set their sights on returning to their former partnership with RGBP now that the company is much further along AND has filed a Master Use IP claim for:
mRNA Cancer Vaccine Check Point Inhibitor Immunotherapy! The ONLY one in existence! This IP has a Trillion Dollar Market potential, due to it being a Master Use clinical application for cancer immunotherapy by mRNA Vaccine.
It's important to keep in mind Lilly's had prior collaboration with RGBP over molecular structures related to their joint claim on NR2F6 which is why one of Lilly's Senior Executives sat on Regen's Scientific Advisory Board as a "Science Officer" who also bought at least 6 M Shares of RGBP Stock which is a matter of record on an SEC filing years ago. His first name if I recall is Jean Pierre
So yes, IMO Eli Lilly has every reason to return to Regen to continue their joint collaboration if not straight up Buy Out the company just to own all of Regen's Valuable Disruptive Biotechnology IP of which there are at least 20.
Well Said! Excellent Post on ALL Points!
... in particular > "They have the checkpoint inhibitor NR2F6 cornered and any discoveries with that will involve partnering with Regen. Also two IND'S of their own are making their way towards FDA approval."
TRADING HALTED!
Yes, Pink Current BUT still categorized as a SHELL COMPANY!
https://www.otcmarkets.com/stock/IDIG/overview